Increased risk of breakthrough infection among cytomegalovirus donor‐positive/recipient‐negative kidney transplant recipients receiving lower‐dose valganciclovir …
DR Stevens, D Sawinski, E Blumberg… - Transplant Infectious …, 2015 - Wiley Online Library
Objective We compared the effectiveness of lower‐dose (LD)(450 mg/day for 6 months) to
standard‐dose (SD)(900 mg/day for 6 months) valganciclovir (VGCV) prophylaxis for …
standard‐dose (SD)(900 mg/day for 6 months) valganciclovir (VGCV) prophylaxis for …
Multicenter evaluation of efficacy and safety of low‐dose versus high‐dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+ …
S Heldenbrand, C Li, RP Cross… - Transplant Infectious …, 2016 - Wiley Online Library
Background The cytomegalovirus (CMV) donor‐positive/recipient‐positive (D+/R+)
population is the largest proportion of renal transplant recipients (RTR). Guidelines for …
population is the largest proportion of renal transplant recipients (RTR). Guidelines for …
Evaluation of low-versus high-dose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients
S Gabardi, N Asipenko, J Fleming, K Lor… - …, 2015 - journals.lww.com
Background Despite proven efficacy of prolonged cytomegalovirus (CMV) prophylaxis using
valganciclovir 900 mg/day, some centers use 450 mg/day due to reported success and cost …
valganciclovir 900 mg/day, some centers use 450 mg/day due to reported success and cost …
[HTML][HTML] Impact of cytomegalovirus disease in D+/R–kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis
FL Luan, M Kommareddi, AO Ojo - American Journal of Transplantation, 2011 - Elsevier
Late-onset cytomegalovirus (CMV) disease remains common in CMV serology naïve kidney
transplant patients of CMV serology positive organs (D+/R–) despite the use of antiviral …
transplant patients of CMV serology positive organs (D+/R–) despite the use of antiviral …
Extended valganciclovir prophylaxis in D+/R− kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the …
A Humar, AP Limaye, EA Blumberg, IA Hauser… - …, 2010 - journals.lww.com
Background. Whether the early reduction in cytomegalovirus (CMV) disease seen at 1 year
with prolongation of antiviral prophylaxis (up to 200 days) persists in the long term is …
with prolongation of antiviral prophylaxis (up to 200 days) persists in the long term is …
Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients
J Kletzmayr, E Kreuzwieser, T Watkins-Riedel… - …, 2000 - journals.lww.com
Background. Although specific therapy is available with ganciclovir, cytomegalovirus (CMV)
disease remains a major problem after renal transplantation especially in CMV seronegative …
disease remains a major problem after renal transplantation especially in CMV seronegative …
Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial
O Witzke, IA Hauser, M Bartels, G Wolf, H Wolters… - …, 2012 - journals.lww.com
Background. Cytomegalovirus (CMV) prevention can be achieved by prophylaxis or
preemptive therapy. We performed a prospective randomized trial to determine whether …
preemptive therapy. We performed a prospective randomized trial to determine whether …
[HTML][HTML] Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized …
O Witzke, M Nitschke, M Bartels, H Wolters… - …, 2018 - journals.lww.com
Background The VIPP study compared valganciclovir prophylaxis with preemptive treatment
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
[HTML][HTML] Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients
JA Khoury, GA Storch, DL Bohl, RM Schuessler… - American Journal of …, 2006 - Elsevier
Prophylaxis reduces cytomegalovirus (CMV) disease, but is associated with increased costs
and risks for side effects, viral resistance and late onset CMV disease. Preemptive therapy …
and risks for side effects, viral resistance and late onset CMV disease. Preemptive therapy …
[HTML][HTML] Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis
I Helanterä, L Kyllönen, I Lautenschlager… - American Journal of …, 2010 - Elsevier
Prolonging cytomegalovirus (CMV) prophylaxis in CMV seronegative recipients of a kidney
from CMV seropositive donor (D+/R–) may reduce the incidence of late infections. We …
from CMV seropositive donor (D+/R–) may reduce the incidence of late infections. We …